Phase i study and preliminary pharmacology of the novel innate immune modulator rBBX-01 in gynecologic cancers

Clinical Cancer Research

Volumn 14, Issue 10, 2008, Pages 3089-3097

  Rader, Janet S ^a,e   Aylsworth, Charles F ^b,c   Juckett, David A ^b,c   Mutch, David G ^a   Powell, Matthew A ^a   Lippmann, Lynne ^a   Dimitrov, Nikolay V ^d  

^a WASHINGTON UNIVERSITY   (United States)

^b Barros Research Institute   (United States)

^c Departments of Chemistry   (United States)

^d MICHIGAN STATE UNIVERSITY   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BBX 01; CA 125 ANTIGEN; GAMMA INTERFERON; IMMUNOSTIMULATING AGENT; INTERLEUKIN 12; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR; PROTOZOAL PROTEIN;

ADULT; ADVANCED CANCER; AGED; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD CHEMISTRY; BLOOD PRESSURE; BODY TEMPERATURE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CYTOKINE PRODUCTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG MEGADOSE; EIMERIA; ENDOMETRIUM CANCER; FEMALE; GRANULOSA CELL TUMOR; HEART RATE; HUMAN; IMMUNOMODULATION; INTERFERON PRODUCTION; KIDNEY FUNCTION; LIVER FUNCTION; LOW DRUG DOSE; MOUSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SIDE EFFECT; UTERINE CERVIX CANCER; VOMITING; ANIMAL; BLOOD; DOSE RESPONSE; DRUG EFFECT; FEMALE GENITAL TRACT TUMOR; HAMSTER; MIDDLE AGED;

ADULT; AGED; ANIMALS; CA-125 ANTIGEN; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; EIMERIA; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MICE; MIDDLE AGED; PROTOZOAN PROTEINS; RECOMBINANT PROTEINS;

EID: 49649097700     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4250     Document Type: Article

References (32)

1. Parmiani G, De Filippo A, Novellino L, Castelli C. Unique human tumor antigens: immunobiology and use in clinical trials. J Immunol 2007;178:1975-9.
2. Vieweg J, Su Z, Dahm P, Kusmartsev S. Reversal of tumor-mediated immunosuppression. Clin Cancer Res 2007;13:727-32s.
3. Dhodapkar MV. Harnessing host immune responses to preneoplasia: promise and challenges. Cancer Immunol Immunother 2005;54:409-13.
4. Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 2005;54;187-207.
5. Nijman HW, Lambeck A, Van Der Burg SH, Van Der Zee AGJ, Daemen T. Immunologic aspect of ovarian cancer and p53 as tumor antigen. J Transl Med 2005;3:1-12.
6. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767-811.
7. Lipscomb MF, Masten BJ. Dendritic cells: immune regulators in health and disease. Physiol Rev 2002;82:97-130.
8. Basset C, Holton J, O'Mahony R, Roitt I. Innate immunity and pathogen-host interaction. Vaccine 2003;21:12-23.
9. Ishii KJ, Uematsu S, Akira S. 'toll' gates for future immunotherapy. Curr Pharm Des 2006;12:4135-42.
10. Hoebe K, Jiang Z, Georgel P, Tabeta K, Janssen E, Du X, Beutler B. TLR signaling pathways: opportunities for activation and blockade in pursuit of therapy. Curr Pharm Des 2006;12:4123-34.
11. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006;6:24-37.
12. Barnett B, Kryczek I, Cheng P, Zou W, Curiel TJ. Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol 2005;54:369-77.
13. Laurent F, Bourdieu C, Kazanji M. Yvore P, Pery P, The immunodominant Eimeria acervulina sporozoite antigen previously described as p160/p240 is a 19-kilodalton antigen present in several Eimeria species. Mol Bioch Parasitol 1994;63:79-86.
14. Korenkova G, Pakandl M. Early events in the life cycle of the mouse coccidium Eimeria falciformis (Eimer, 1870) Schneider, 1875 in naive and immune hosts. Parasite 2004;11:333-9.
15. Rosenberg B, Juckett DA, Aylsworth CF, et al. Protein from intestinal Eimeria protozoan stimulates IL-12 release from dendritic cells, exhibits antitumor properties in vivo and is correlated with low intestinal tumor-igenicity. Int J Cancer 2005;114:756-65.
16. Gowen BB, Smee DF, Wong M-H, et al. Recombinant Eimeria protozoan protein elicits resistance to acute phlebovirus infection in mice but not hamsters. Antimicrob Agents Chemother 2006;50:2023-9.
17. Julander JG, Judge JW, Olsen AL, Rosenberg B, Schafer K, Sidwell RW. Prophylactic treatment with recombinant Eimeria protein, alone or in combination with an agonist cocktail, protects mice from Banzi virus infection. Antiviral Res 2007;75:14-9.
18. Yarovinsky F, Zhang DK, Andersen JF, et al. TLR11 activation of dendritic cells by a protozoan profilin-like protein. Science 2005;308:1626-9.
19. Eisenhauer EA, O'Dwyer PJ, Christian M, Humphrey JS. Phase I clinical trial design in cancer drug development. J Clin Oncol 2000;18:684-92.
20. Cheng HC, Lai RW. Use of the proportionality equations for analysis of dose-response curves. Pharmacol Res 2003;47:163-73.
21. Hayashi N, Kinoshita H, Yukawa E, Higuchi S. Pharmacokinetic and pharmacodynamic analysis of subcutaneous recombinant human granulocyte colony stimulating factor (Lenograstim) administration. J Clin Pharmacol 1999;39:583-92.
22. Basche M, Gustafson DL, Holden SN, et al. A phase I biological and pharmacologic study of the hepara-nase inhibitor PI-88 in patients with advanced solid tumors. Clin Cancer Res 2006;12:5471-80.
23. 2Gossner G, Coleman RL, Mutch DG, et al. CA125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan. Gynecol Oncol 2006;103:212-8.
24. Gronlund B, Hogdall C, Hilden J, Engelholm SA, Hogdoll EVS, Hansen HH. Should CA125 Response Criteria be preferred to Response Evaluation Criteria in Solid Tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma? J Clin Oncol 2004;22:4051-8.
25. Rustin GJS, Nelstrop AE, McClean P, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996;14:1545-51.
26. Rustin GJ. Can we now agree to use the same definition to measure response according to CA125? J Clin Oncol 2004;22:4035-6.
27. Rustin GJS, Quinn M, Thigpen T, et al. Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 2004;96:487-8.
28. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
29. Kovacs E. Serum levels of IL-12 and the production of IFN-γ, IL-2 and IL-4 by peripheral blood mononuclear cells (PBMC) in cancer patients treated with Viscum album extract. Biomed Pharmacother 2000;54:305-10.
30. Brunda MJ, Luistro L, Rumennik L, et al. Antitumor activity of interleukin 12 in preclinical models. Cancer Chemother Pharmacol 1996;38:S16-21.
31. Coughlin CM, Salhany KE, Wysocka M, et al. Inter-leukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest 1998;101:1441-52.
32. Eisenbeis CF, Lesinski GB. Anghelina M, et al. Phase I study of the sequential combination of in-terleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12. J Clin Oncol 2005;23:8835-44.